ES2185237T3 - 1-(asamantil)amidinas y su utilizacion en el tratamiento de estados generalmente asociados con anomalias en la transmision glutamatergica. - Google Patents

1-(asamantil)amidinas y su utilizacion en el tratamiento de estados generalmente asociados con anomalias en la transmision glutamatergica.

Info

Publication number
ES2185237T3
ES2185237T3 ES98959052T ES98959052T ES2185237T3 ES 2185237 T3 ES2185237 T3 ES 2185237T3 ES 98959052 T ES98959052 T ES 98959052T ES 98959052 T ES98959052 T ES 98959052T ES 2185237 T3 ES2185237 T3 ES 2185237T3
Authority
ES
Spain
Prior art keywords
treatment
generally associated
transmission
glutamatergical
asamantil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98959052T
Other languages
English (en)
Inventor
Roger John Gillespie
Michael Fredrick Snape
Simon Edward Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Research Ltd
Original Assignee
Vernalis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Research Ltd filed Critical Vernalis Research Ltd
Application granted granted Critical
Publication of ES2185237T3 publication Critical patent/ES2185237T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/16—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Soy Sauces And Products Related Thereto (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Utilización de un compuesto de fórmula (1):**Fórmula** en la que X es una cadena de alquileno sustituido o no sustituido que contiene 0, 1, 2, 3 ó 4 átomos de carbono, donde uno o más átomos de carbono de la cadena X puede estar sustituido independientemente por grupo(s) sustituyente(s) seleccionado(s) de alquilo y arilo; R1, R2 y R3 son seleccionados independientemente de hidrógeno, alquilo y arilo; R4, R5 y R6 son seleccionados independientemente de hidrógeno, alquilo, arilo, halógeno y alcoxi; y sales del mismo farmacéuticamente aceptables; donde dicho grupo alquilo se define como un radical hidrocarbilo ramificado o no ramificado, cíclico o acíclico, saturado o insaturado, y dicho grupo arilo se define como un grupo aromático o heteroaromático, en la fabricación de un medicamento para ser utilizado en el tratamiento de una condición asociada generalmente con anormalidades en la transmisión glutamatérgica.
ES98959052T 1997-12-12 1998-12-11 1-(asamantil)amidinas y su utilizacion en el tratamiento de estados generalmente asociados con anomalias en la transmision glutamatergica. Expired - Lifetime ES2185237T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9726388.3A GB9726388D0 (en) 1997-12-12 1997-12-12 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2185237T3 true ES2185237T3 (es) 2003-04-16

Family

ID=10823580

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98959052T Expired - Lifetime ES2185237T3 (es) 1997-12-12 1998-12-11 1-(asamantil)amidinas y su utilizacion en el tratamiento de estados generalmente asociados con anomalias en la transmision glutamatergica.

Country Status (9)

Country Link
US (2) US6500866B1 (es)
EP (1) EP1037874B1 (es)
JP (1) JP2002508350A (es)
AT (1) ATE225768T1 (es)
AU (1) AU1498299A (es)
DE (1) DE69808669T2 (es)
ES (1) ES2185237T3 (es)
GB (1) GB9726388D0 (es)
WO (1) WO1999031051A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100504A2 (en) 1998-07-02 2001-05-23 Eisai Co., Ltd. Pharmaceutical compositions and their uses for treatment of demyelinating disorders
GB9901691D0 (en) 1999-01-26 1999-03-17 Cerebrus Ltd Chemical compounds
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
ITTO20030668A1 (it) * 2003-09-02 2005-03-03 Rotta Res Lab S P A O Ra Rottapharm Derivati dell'adamantano dotati di attivita' neuroprotettiva, antidepressiva e anti-ischemica e procedimento per la loro preparazione.
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
HUP0401523A3 (en) * 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
RU2434848C2 (ru) * 2009-11-30 2011-11-27 Учреждение Российской Академии Наук Институт Нефтехимии И Катализа Ран Способ получения 1-хлор-3-цианоадамантана

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE151447C (es)
BE795381A (fr) * 1972-02-15 1973-08-13 Sandoz Sa Derives de l'adamaniane
JPS5246949B2 (es) * 1973-10-19 1977-11-29
DD151447A1 (de) * 1980-06-18 1981-10-21 Heinz Paul Verfahren zur herstellung von amidinen und deren salzen
CA2089261A1 (en) * 1990-08-30 1992-03-01 John F.W. Keana Substituted amidines having high binding to the sigma receptor and the use thereof
US5677349A (en) * 1995-04-27 1997-10-14 Gilad; Gad M. Agmatine for the treatment of neurotrauma and neurodegenerative diseases

Also Published As

Publication number Publication date
DE69808669D1 (de) 2002-11-14
EP1037874B1 (en) 2002-10-09
DE69808669T2 (de) 2003-07-31
US6500866B1 (en) 2002-12-31
JP2002508350A (ja) 2002-03-19
GB9726388D0 (en) 1998-02-11
AU1498299A (en) 1999-07-05
ATE225768T1 (de) 2002-10-15
WO1999031051A1 (en) 1999-06-24
EP1037874A1 (en) 2000-09-27
US20030130354A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
GB0018272D0 (en) Chemical compounds IV
ATE248824T1 (de) Substituierte phenylderivate, ihre herstellung und verwendung
EP0842661A3 (en) Atherosclerosis treatment
DE69315050D1 (de) Fluorinierte 17-Beta substituierte 4-Aza-5-Alpha-Androstan-3-On Derivate
MY117092A (en) Chemotherapeutic pyrrolocarbazole derivatives
LU92263I2 (fr) Imépitoïne et ses dérivés pharmaceutiquement acceptables (PEXION)
AU2001293707A1 (en) Anti-inflammatory medicament
AU1498299A (en) 1-(adamantyl)amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
DE69810960D1 (de) 2-phenoxyanilin-derivate
IL132575A0 (en) Benzimidazole derivative
AU2116900A (en) 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
WO1999038841A8 (en) Adamantanecarboximidamide derivatives and their use as nmda antagonists
DE69810622D1 (de) Naphthothiazolon-derivate die auf den dopaminergen rezeptor d 3 wirken
PT1049672E (pt) Derivados de azetidinocarboxamida para o tratamento de disturbios do snc
NZ291855A (en) Bridged azabicyclo-piperazin-1-yl-2-phenyl-butan-1-one derivatives as 5-ht1a antagonists
SE9800932D0 (sv) New compunds
AU2178099A (en) Azetidinecarboxamide derivatives for treating cns disorders
TW358809B (en) Phenylamidinothiophene compound and anti-inflammatory agent containing the same
MX9706627A (es) Derivado de tiazolidinona opticamente activo.
MX9800925A (es) Uso de derivados de adamantano para tratar enfermedades del oido interno.
ES2107971A1 (es) Combinacion estabilizante.